Cure8 news brief
An at‑home subcutaneous induction option for Skyrizi could make starting this IL‑23 inhibitor easier for many adults with moderate‑to‑severe Crohn’s disease, reducing the need for clinic infusions and possibly improving convenience and adherence.
Coverage, clinician uptake, and label details (including TB guidance) will shape real‑world access.
Adults with moderate‑to‑severe Crohn’s disease considering biologic therapy; patients already on or switching to Skyrizi; gastroenterology clinicians and infusion/infusion-alternative service planners; payer and access stakeholders.
AbbVie announced an FDA approval expanding Skyrizi (risankizumab) to allow a subcutaneous (SC) induction regimen for adults with moderately to severely active Crohn’s disease, enabling at-home initiation via an on‑body injector and continued dosing every eight weeks for maintenance starting at week 12.
The article notes the approval is a label expansion building on prior Crohn’s disease approvals and references updated tuberculosis (TB) label language that may affect prestart evaluation.
What this appears to change practically is that people eligible for Skyrizi could begin induction at home with an on‑body injector rather than needing an infusion-center start, and then continue on an every‑8‑week SC maintenance schedule.
The piece is framed as a commercial and access development (easier starts, potential for higher uptake) and cites the AFFIRM program meeting co‑primary endpoints at week 12 as the basis for the label expansion.
this summary is based on the tradingview article (sourced from a PR Newswire/AbbVie release) and not an independent review of the FDA label text or clinical trial publications.
For individual treatment decisions, talk with your clinician about whether this formulation and dosing schedule are appropriate and about any TB screening or monitoring recommended by the label.
The article is a business/press-release style report summarizing an FDA label expansion. It references trial program results (AFFIRM) and commercial implications; readers should consult the official FDA approval/label and discuss clinical implications with their care team. This is not medical advice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This change may make starting Skyrizi easier and more convenient by allowing induction to be done at home rather than IV infusions in a clinic. It expands options among IL‑23 p19 inhibitors for people with moderate to...
An FDA approval of a subcutaneous induction option for risankizumab means adults with moderate-to-severe Crohn's disease can start treatment at home using an on-body injector, which may make starting therapy more...
A subcutaneous induction option for SKYRIZI could let people with Crohn’s start and continue treatment with injections instead of beginning with an IV infusion, which may affect convenience, time in clinic, and infusion...
